La vendita allo scoperto per Telomir Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Telomir Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Telomir Pharmaceuticals (NASDAQ:TELO) Azioni, Report sulle vendite allo scoperto

Telomir Pharmaceuticals

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals Inc

TELO GENOMICS CORP by Telo Genomics Corp.

Telo Genomics Corp

Telos - United States Dollar

Telos Corp

UBS analyst David Vogt maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Sell and raises the price target from $170 to $195.

News

Price Target

Analyst Ratings

UBS Maintains Sell on IBM, Raises Price Target to $195

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $142 to $145.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $145

UBS analyst Joshua Spector maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Neutral and raises the price target from $54 to $57.

UBS Maintains Neutral on Corning, Raises Price Target to $57

UBS analyst Joshua Spector maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Neutral and raises the price target from $41 to $45.

UBS Maintains Neutral on FMC, Raises Price Target to $45

B of A Securities analyst George Staphos maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Buy and raises the price target from $110 to $117.

B of A Securities Maintains Buy on Crown Holdings, Raises Price Target to $117

UBS analyst Joshua Spector maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Buy and raises the price target from $25 to $29.

UBS Maintains Buy on Element Solutions, Raises Price Target to $29

Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) has outperformed the market over the past 5 years by 15.74% on an annualized basis producing an average annual return of 30.08%. Currently, Viper Energy has a market capitalization of $4.93 billion. 
Buying $100 In VNOM: If an investor had bought $100 of VNOM stock 5 years ago, it would be worth $389.87 today based on a price of $37.64 for VNOM at the time of writing.
<h3>Viper Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752072327_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VNOM

Here's How Much You Would Have Made Owning Viper Energy Stock In The Last 5 Years

UBS analyst Joshua Spector maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Neutral and raises the price target from $271 to $288.

UBS Maintains Neutral on Ecolab, Raises Price Target to $288

<a href="https://x.com/lindayaX/status/1942957094811951197" title="https://x.com/lindayaX/status/1942957094811951197">https://x.com/lindayaX/status/1942957094811951197</a>

Management

X CEO Linda Yaccarino Writes "After two incredible years, I've decided to step down as CEO of X. ...."

B of A Securities analyst George Staphos maintains Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) with a Buy and lowers the price target from $31 to $28.

B of A Securities Maintains Buy on Graphic Packaging Holding, Lowers Price Target to $28

CLDI

Calidi Biotherapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 195.5%

B of A Securities analyst George Staphos maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Buy and raises the price target from $195 to $208.

B of A Securities Maintains Buy on Avery Dennison, Raises Price Target to $208

UBS analyst Joshua Spector maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and raises the price target from $85 to $87.

UBS Maintains Buy on DuPont de Nemours, Raises Price Target to $87

UBS analyst Joshua Spector maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $76 to $90.

CTVA

UBS Maintains Buy on Corteva, Raises Price Target to $90

UBS analyst Joshua Spector maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and raises the price target from $51 to $66.

UBS Maintains Neutral on Celanese, Raises Price Target to $66

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares continued their meteoric rise on Wednesday, as the stock surged to a new all-time high and propelled its market capitalization beyond the historic $4 trillion threshold. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/NVDA/news">need to know</a>.
What To Know: Wednesday&#8217;s rally follows a pivotal announcement that has quelled market uncertainty. On Monday, key customer OpenAI <a href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale">publicly reaffirmed</a> its commitment to using Nvidia&#8217;s AI chips at scale, dispelling rumors of a potential shift to Google's competing hardware. 
This endorsement helps solidify Nvidia&#8217;s position as the foundational hardware provider for the world&#8217;s leading AI models. Further <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46253485/nvidia-stock-hits-new-all-time-highs-whats-driving-the-record-breaking-run">bolstering sentiment</a> is the passing of the "Big Beautiful Bill," which aims to increase the U.S. semiconductor investment tax credit, and news that key supplier TSMC is accelerating its American expansion, shoring up Nvidia&#8217;s supply chain.
Despite the bullish momentum, the company is still navigating persistent geopolitical headwinds. The U.S. government is <a href="https://www.benzinga.com/markets/asia/25/07/46266218/us-plans-to-restrict-ai-chip-exports-to-malaysia-thailand-to-curb-diversion-to-china">reportedly drafting</a> new rules to restrict AI chip exports to China through intermediary countries like Malaysia and Thailand, expanding on existing controls that have previously impacted Nvidia&#8217;s revenue projections.
Last week, investor anticipation was <a href="https://www.benzinga.com/markets/tech/25/07/46261478/nvidias-4t-countdown-will-next-weeks-chart-print-a-trillion-dollar-breakout">fueled</a> by a Morgan Stanley note citing &#8220;very strong demand for all Blackwell form factors&#8221; and new partnerships in Europe offsetting weaker sales in China. 
The optimism was compounded as competitive threats from rivals appeared to fade, with reports of Microsoft facing delays in its own chip development and OpenAI confirming it would not scale back its use of Nvidia hardware. 
Despite its astronomical rise, Nvidia&#8217;s valuation remains reasonable, with a forward P/E ratio <a href="https://www.benzinga.com/markets/tech/25/07/46261478/nvidias-4t-countdown-will-next-weeks-chart-print-a-trillion-dollar-breakout">comparable to industry peers</a>.
Benzinga Edge Rankings: Based on the provided <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> rankings, NVDA shows exceptional strength in Growth with a score of 98.59, and very strong Momentum at 76.28. These high scores suggest the stock has demonstrated powerful upward price movement and is backed by significant growth indicators.
However, its Value score is notably low at 6.94, which indicates that the stock may be considered overvalued compared to its peers or intrinsic worth.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVDA shares are trading higher by 1.67% to $162.66 Wednesday morning. The stock has a 52-week high of $164.42 and a 52-week low of $86.63.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46315651/nvidia-broadcom-avgo-stock-ai">Nvidia Is The Star―But Broadcom Is The AI Boom&#8217;s Best-Kept Secret</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
By now you're likely curious about how to participate in the market for NVIDIA &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of NVIDIA, which is trading at $162.66 as of publishing time, $100 would buy you 0.61 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

NVDA

Nvidia Hits $4 Trillion Market Cap, Stock Surges To All-Time High

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.46% to 44,442.42 while the NASDAQ gained 0.95% to 20,611.65. The S&amp;P 500 also rose, gaining, 0.60% to 6,262.70.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 1.6% on Wednesday.
In trading on Wednesday, energy stocks dipped by 0.6%.
Top Headline
U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May in-line with the preliminary estimate and compared to a 0.1% increase in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Calidi Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) shares shot up 242% to $1.1463. The stock's surge comes on the heels of a development in the healthcare sector. Calidi Biotherapeutics has been making headlines for its innovative approaches to cancer treatment.</li>
<li>Shares of SU Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) got a boost, surging 203% to $1.36 after the company was awarded an HK$88.5 million hospital contract.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 150% to $6.65 after the company announced it received a notice of allowance for the U.S. patent application covering GIMOTI in patients with moderate to severe symptoms of Gastroparesis.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Park Ha Biological Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) shares dropped 53% to $1.4001.</li>
<li>Shares of RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) were down 40% to $7.68 after the company cut its 2025 revenue guidance from $160M–$175M to $120M–$130M.</li>
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) was down, falling 33% to $36.50.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $67.82 while gold traded down 0.1% at $3,315.70.
Silver traded down 0.5% to $36.575 on Wednesday, while copper fell 3% to $5.5145.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.8%, while Spain's IBEX 35 Index rose 1%. London's FTSE 100 gained 0.1%, Germany's DAX 40 gained 1.4% and France's CAC 40 gained 1.4% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei gaining 0.33%, Hong Kong's Hang Seng falling 1.06%, China's Shanghai Composite declining 0.13% and India's BSE Sensex falling 0.21%.
Economics
U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May in-line with the preliminary estimate and compared to a 0.1% increase in the previous month.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46320283/this-microsoft-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday">This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

EVOK

RXST

SUGP

Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May

Stifel analyst Ralph Profiti initiates coverage on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Buy rating and announces Price Target of $73.

Initiation

Stifel Initiates Coverage On Newmont with Buy Rating, Announces Price Target of $73

<a href="https://www.globenewswire.com/Tracker?data=Y8xhIaAzqODKu2iemiaRoq9kdZ7pTZ9Qpuh-hfA5-GYzDUxsBDzFxRqQJd8_A8FYbGu8YCPxKRU7PqquCwymioWn0jDjeIb_Wo4NNFwNf8k=">Richardson Electronics, Ltd.</a> (NASDAQ: RELL) today announced a global technology partner agreement with Pakal Technologies, Inc., a cutting-edge innovator in silicon power semiconductor solutions. Under this agreement, Richardson Electronics will partner with Pakal to supply customers with Pakal's advanced 650V and 1200V silicon-based power switches—delivering breakthrough efficiency to customers worldwide.
Pakal Technologies has developed the groundbreaking IGTO(t) - Insulated Gate Turn-Off Thyristor structure. This is the first new high-voltage silicon power semiconductor to be released since the IGBT was introduced 40 years ago. The IGTO(t) is a direct drop-in upgrade for modern IGBTs. Pakal Technologies' IGTO(t) offers up to 30% lower conduction losses compared to modern IGBTs with high frequency switching and improved thermal performance - and cost-effective silicon pricing. The IGTO(t) is a game-changing component for applications in electric vehicles (EVs), renewable energy systems, welding, solar, ANPC 3-level topology, robotics, induction heating, industrial power conversion, and many others.

RELL

Richardson Electronics Partners With Pakal Technologies To Deliver Advanced 650V And 1200V Silicon-Based Power Switches, Featuring New IGTO(t) Technology

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares are on watch Wednesday after the company announced that it became the first AI cloud provider to offer <a href="https://www.benzinga.com/pressreleases/25/07/n46316961/coreweave-becomes-the-first-ai-cloud-provider-to-offer-nvidia-rtx-pro-6000-blackwell-gpu-at-scale">Nvidia RTX Pro 6000 Blackwell GPUs at scale</a>.
What Happened: CoreWeave announced the general availability of Nvidia RTX Pro 6000 Blackwell server edition&nbsp;instances, offering up to 5.6x faster LLM inferencing and 3.5x faster text-to-video generation&nbsp;compared to the prior generation offering.
When combined with CoreWeave&#8217;s <a href="http://benzinga.com/topic/AI">AI</a> cloud platform, the new offering gives customers access to a cheaper alternative to larger GPU clusters for building and scaling AI applications. 
&#8220;CoreWeave is built to move at the speed of innovation, and with the new RTX PRO 6000-based instances, we&#8217;re once again first to bring advanced AI and graphics technology to the cloud,&#8221; said&nbsp;Peter Salanki, co-Founder and chief technology officer of CoreWeave. 
&#8220;This is a major step forward for customers building the future of AI, as it gives them the ability to optimize and scale on GPU instances that are ideal for their applications, and a testament to the speed and reliability of our AI cloud platform.&#8221;
CoreWeave shares are bouncing back Wednesday after trading lower to start the week after the company announced a $9 billion <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal">all-stock deal</a> to acquire Core Scientific. The deal, which&nbsp;is anticipated to close in the fourth quarter, is expected to help CoreWeave verticalize its data center footprint.
<h3 class="wp-block-heading">How To Buy CRWV Stock</h3>
By now you're likely curious about how to participate in the market for CoreWeave &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
CRWV Price Action: <a href="http://benzinga.com/quote/crwv">CoreWeave shares</a> were down 1.01% at $149.82 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46306575/why-coreweaves-9-billion-deal-isnt-about-chips">Why CoreWeave&#8217;s $9 Billion Deal Isn&#8217;t About Chips</a></li>
</ul>
Photo: courtesy of CoreWeave.

Movers

CRWV

CoreWeave Stock Is Bouncing Back Wednesday: What's Happening?

Press Releases

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

TELO

AN2 Therapeutics

Assertio Holdings

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hyperion DeFi

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Pulmatrix

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

VYNE Therapeutics

Screenshot 2024-12-16 at 6.39.22 PM

Biotech

General

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation

Comments

Telomir Pharmaceuticals

Vendite allo scoperto

Telomir Pharmaceuticals (NASDAQ:TELO) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO